Pharma giant Eli Lilly announced Monday it’s purchasing Loxo Oncology for $8 billion, in another step to broaden its cancer treatment portfolio.
Jan. 7 (UPI) — Pharma giant Eli Lilly announced Monday it’s purchasing Loxo Oncology for $8 billion, in another step to broaden its cancer treatment portfolio.
Indianapolis-based Eli Lilly said it will purchase stock from Loxo Oncology, a Connecticut biopharmaceutical company focused on developing and selling selective medicines for patients with genomically-defined cancers, for $235 per share.
